Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | MC3R | P41968 | 2/20 | 0.40 |
| ▸ | MC1R | Q01726 | 2/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559140 | 1.00 | CACNA1G (0.43) | CACNA1GNAAAFAAHCNR1SIGMAR1 | |
| SCHEMBL2559137 | 1.00 | CACNA1G (0.43) | CACNA1GNAAAFAAHCNR1SIGMAR1 | |
| SCHEMBL1915646 | 0.92 | NAAA (0.47) | NAAAFAAHIL6STALDH1A1MC4R | |
| SCHEMBL7346791 | 0.92 | NAAA (0.47) | NAAAFAAHIL6STALDH1A1MC4R | |
| SCHEMBL1915643 | 0.92 | NAAA (0.47) | NAAAFAAHIL6STALDH1A1MC4R | |
| SCHEMBL23866771 | 0.88 | NAAA (0.51) | NAAAFAAHIL6STPKMALDH1A1 | |
| SCHEMBL23902846 | 0.88 | NAAA (0.51) | NAAAFAAHIL6STPKMALDH1A1 | |
| SCHEMBL23860312 | 0.88 | NAAA (0.42) | NAAAFAAHSIGMAR1IL6STMC4R | |
| SCHEMBL21871072 | 0.88 | NAAA (0.42) | NAAAFAAHSIGMAR1IL6STMC4R | |
| SCHEMBL23522276 | 0.88 | NAAA (0.51) | NAAAFAAHIL6STPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | CACNA1G 4528/4885NAAA 4222/4885FAAH 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.